Clinical Trials on Human African Trypanosomiasis (HAT)

Total 279 results

Yun Long

Completed

Application of Indicator Based-electrical Impedance Tomography Method Assess Lung Regional Perfusion in ICU Patients

Respiratory Failure | Hypoxemia | ARDS, Human

China
Bristol-Myers Squibb

Completed

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Hepatitis C

China, Korea, Republic of, Taiwan
Southeast University, China

Unknown

Glycocalyx Biomarkers in ARDS for Clinical Prognosis and Pulmonary Fibrosis

Endothelial Dysfunction | ARDS, Human | Mechanical Ventilation Pressure High

China
Brooke Army Medical Center

Completed

Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba

Hepatitis c

United States
Peninsula Health
Baxter Healthcare Corporation; Monash University

Recruiting

Extracorporeal Carbon Dioxide Removal Using PrismaLung in Reducing Ventilator Induced Lung Injury

ARDS, Human

Australia
Hôpital Européen Marseille

Terminated

Enhanced Lung Protective Ventilation With ECCO2R During ARDS (PROVE)

Ventilator-Induced Lung Injury | ARDS, Human

France
Peking Union Medical College Hospital

Completed

Effect of Initial Empirical PEEP Setting on the Esophageal Pressure-guided PEEP Titration in ARDS

ARDS, Human | PEEP, Occult | Esophageal and Pleural Pressure

China
Northern State Medical University

Completed

The Effect pf Goal-directed De-escalation in ARDS on Organ Function and Mortality

ARDS, Human | Sepsis, Severe

Russian Federation
University of Florida
AbbVie; University of North Carolina, Chapel Hill

Completed

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

Hepatitis C | HCV

United States
Khon Kaen University

Terminated

Cryotherapy for Human Papillomavirus Clearance in Biopsy-confirmed Cervical Low-grade Squamous Intraepithelial Lesions (Cryotherapy)

Human Papillomavirus Clearance at 12 Months

Thailand
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France

Recruiting

Transpulmonary Pressure - Guided Mechanical Ventilation in Morbidly Obese ARDS Patients: a Feasibility Study. (TGV-MOA)

Obesity, Morbid | ARDS, Human

France
Aljazeera Hospital
National Research Centre, Egypt

Completed

Screening Hepatitis Positive Women for Congenital Anomalies

Hepatitis C

Egypt
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Malaysia
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix®

Dengue Fever | Dengue Hemorrhagic Fever | Human Papillomavirus Disease

Mexico
Uppsala University
Center for Clinical Research Dalarna, Sweden

Completed

The Impact of Premorbid Illnesses on the Risk of ICU Admission and Short-term Outcome

Sepsis | Corona Virus Infection | ARDS, Human

Sweden
Merck Sharp & Dohme LLC

Completed

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Naïve Hepatitis C Virus Participants (MK-5172-067)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

Hepatitis C
Boehringer Ingelheim

Completed

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

Hepatitis C, Chronic

United States, Argentina, Australia, Austria, Canada, Czech Republic, France, Germany, Korea, Republic of, Netherlands, Portugal, Romania, Spain, Switzerland, United Kingdom
Merck Sharp & Dohme LLC

Withdrawn

Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Boceprevir/Pegylated Interferon/Ribavarin for Chronic Hepatitis C Infection (MK-5172-066)

Hepatitis C
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)

Hepatitis C
Brooke Army Medical Center
The Geneva Foundation

Completed

The Effects of Mogroside Sweetener on Viral Load in TreatmenT Naive Genotype 1 (GT 1) Subjects CHC (PureLo)

Hepatitis C

United States
Jonsson Comprehensive Cancer Center
AstraZeneca

Terminated

Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Pathologic... and other conditions

United States
Shanghai Zhongshan Hospital

Enrolling by invitation

Potential Biomarkers for Reflux Aspiration-induced Lung Injury.

Aspiration Pneumonia | ARDS, Human

China
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of Grazoprevir (MK-5172), Elbasvir (MK-8742), and Sofosbuvir for Chronic Infection With Hepatitis C Virus Genotypes 1 and 3 (MK-5172-074)

Hepatitis C
Syneos Health
Merck Sharp & Dohme LLC; Sandoz; Teva Pharmaceuticals USA; Aurobindo Pharma Ltd; Zydus...

Terminated

The Ribavirin Pregnancy Registry (RPR)

Hepatitis C | Pregnancy Complications | Birth Defects

United States
Humanity & Health Medical Group Limited

Withdrawn

Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b Infection

HCV Infection

Hong Kong
University Hospital, Clermont-Ferrand
Merck Sharp & Dohme LLC

Completed

Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis (STREAGER)

Chronic HCV Infection

France
Gilead Sciences

Completed

Sofosbuvir With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection (NEUTRINO)

Chronic Hepatitis C

United States, Puerto Rico
AVM Biotechnology Inc
Medpace, Inc.

Not yet recruiting

Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS (AVM0703)

Covid19 | Influenza, Human | ARDS
AbbVie

Completed

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (MAGELLAN-3)

Hepatitis C Virus Infection

United States, Australia, Canada, China, Germany, Korea, Republic of, New Zealand, Russian Federation, Spain, Sweden, Switzerland, United Kingdom
Lawson Health Research Institute
London Health Sciences Centre

Completed

London's Exogenous Surfactant Study for COVID19 (LESSCOVID)

COVID-19 | ARDS, Human

Canada
University Hospital Tuebingen
University Hospital Muenster; RWTH Aachen University; University Hospital Freiburg

Withdrawn

Early Versus Late ECMO Therapy in COVID-19 Induced ARDS (ECMO-VID) (ECMO-VID)

COVID-19 | ARDS, Human

Germany
Merck Sharp & Dohme LLC

Completed

Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination for Chronic Hepatitis C Virus (HCV) Genotypes 1, 4, and 6 (MK-5172-065)

Hepatitis C
Brooke Army Medical Center
InterMune

Completed

Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

Hepatitis C

United States
Hospital San Carlos, Madrid
FUNDACION PARA LA INVESTIGACION HOSPITAL CLINICO SAN CARLOS

Unknown

The Critical Care Response to the COVID-19 Pandemic in Madrid (Tetrix)

COVID-19 | ARDS, Human

Spain
University of Minnesota

Recruiting

Treatment of ARDS With Instilled T3 (ARDS+T3)

Thyroid | Pulmonary Edema | ARDS, Human | Lung Inflammation | Lung, Wet

United States
Cocrystal Pharma, Inc.

Completed

Study of CDI-31244 in Combination With Sofosbuvir (SOF) and Velpatasvir (VEL)

Chronic Hepatitis C

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)

Hepatitis C Virus Infection
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Chronic Hepatitis C
University Hospital, Toulouse

Completed

WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound. (INVICTUS)

COVID-19 | ARDS, Human | Mechanical Ventilation

France
Northwell Health
Feinstein Institute for Medical Research; BioSymetrics

Completed

Associations Between COVID-19 ARDS Treatment, Clinical Trajectories and Liberation From Mechanical Ventilator - an Analysis of the NorthCARDS Dataset (NorthCARDS)

Covid19 | ARDS, Human

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Chronic Hepatitis C Virus

United States, France, Italy, United Kingdom, Germany, Spain, Puerto Rico
Hoffmann-La Roche

Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin in Hemophiliac Patients With Chronic Hepatitis C.

Hepatitis C, Chronic

Mexico
University of Hamburg-Eppendorf
Hoffmann-La Roche; Universitätsklinikum Hamburg-Eppendorf

Unknown

Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy

Hepatitis C, Chronic | Relapse

Germany
Corporacion Parc Tauli
Institut de Ciències Fotòniques (ICFO); Centre de Recerca Matemàtica; Institute...

Recruiting

Prone Positioning Short-term Effects on Tissue Oxygen Saturation in Critical COVID-19 Patients (PRONECOVID19)

Covid19 | ARDS, Human

Spain, Mexico, Brazil
Longeveron Inc.

Active, not recruiting

Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Lomecel-B (RECOVER) (RECOVER)

Covid19 | ARDS, Human

United States
Gilead Sciences

Completed

Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Chronic Hepatitis C Virus

United States
University of Modena and Reggio Emilia
Merck Sharp & Dohme LLC

Unknown

Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC) (MEN_BOC)

Menopause | Chronic Hepatitis C

Italy
University of Turin, Italy

Completed

ECMO for COVID-19 vs Influenza A H1N1 Associated ARDS (InfluCOV_ECMO)

COVID-19 | ARDS | H1N1 Influenza

Italy

3

Subscribe